一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 検索用
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 全文PDF

Abstract

Full Text of PDF Full Text of PDF (634k)
Article in Japanese

Case Report

Monitoring plasma drug concentrations in lung cancer patients on hemodialysis after chemotherapy: Review of 14 cases in Japan, including our own

Yasumiko Sakamotoa  Aiko Masunagaa  Ryo Satoa  Sho Saekia  Hidenori Ichiyasua  Ji-ichiro Sasakia  Akinobu Hamadab  Hirotsugu Kohrogia 

aDepartment of Respiratory Medicine, Kumamoto University Hospital
bDepartment of Pharmacy, Kumamoto University Hospital

ABSTRACT

We investigated the pharmacokinetics of carboplatin (CBDCA) in two patients with lung cancer on hemodialysis (HD) by measuring the plasma concentrations of free platinum. Blood was sampled from the two at the start and end of HD. One patient with small cell lung cancer (SCLC) was treated with CBDCA and etoposide, and the other with non-small cell lung cancer (NSCLC) was treated with CBDCA and paclitaxel. Plasma concentrations of platinum before the first HD were 6.76 to 8.16 μg/ml. The mean reduction rate of concentration (after HD/before HD) was 16.4 ± 6.1%, which suggested that HD was highly effective in removing CBDCA. From the second HD, plasma concentrations of platinum at the end of HD were lower than those at the start of the next HD. Thus we speculated that CBDCA is stored in the tissues and then flows back into bloodstream after the plasma concentration of platinum is decreased by HD. Adverse events of grades 3 to 4 neutropenia and thrombocytopenia were observed. The monitoring of free plasma concentrations of platinum is helpful for avoiding severe adverse effects in lung cancer patients on HD.

KEYWORDS

Chronic renal failure  Maintenance dialysis  Lung cancer  Chemotherapy  Therapeutic drug monitoring 

Received 28 Dec 2012 / Accepted 4 Apr 2013

AJRS, 2(5): 573-577, 2013

Google Scholar